Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 867-878 , July 2007

Neurocognitive Deficits in Adolescents With Schizophrenia: Longitudinal Stability and Predictive Utility for Short-Term Functional Outcome

,Accepted 6 February 2007.

REFERENCES 

  1. Addington J, Addington D. Neurocognitive and social functioning in schizophrenia: a 2.5 year follow-up study. Schizophr Res. 2000;44:47–56
  2. American Psychiatric Association . Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Press; 1994;
  3. Andreasen N. Scale for the Assessment of Negative Symptoms (SANS). Iowa City: University of Iowa; 1982;
  4. Barch DM, Carter CS. Amphetamine improves cognitive function in medicated individuals with schizophrenia and healthy volunteers. Schizophr Res. 2005;77:43–58
  5. Bell MD, Bryson GJ, Greig TC, Fiszdon JM, Wexler BE. Neurocognitive enhancement therapy with work therapy: productivity outcomes at 6-and 12-month follow-ups. J Rehabil Res Dev. 2005;42:829–838
  6. Bilder RM, Goldman RS, Robinson D, et al. Neuropsychology of first-episode schizophrenia: initial characterization and clinical correlates. Am J Psychiatry. 2000;157:549–559
  7. Bird HR. The assessment of functional impairment. In:  Schaffer D,  Lucas CP,  Richters JE editor. Diagnostic Assessment in Child and Adolescent Psychopathology. New York: Guilford; 1999;p. 209–229
  8. Bruininks RH, Woodcock RW, Weatherman RF, Hill BK. Scales of Independent Behavior Revised. Itasca, IL: Riverside; 1996;
  9. Cannon TD, van Erp TG, Bearden CE, et al. Early and late developmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull. 2003;29:653–659
  10. Cannon-Spoor HE, Potkin SG, Wyatt RJ. Measurement of premorbid adjustment in chronic schizophrenia. Schizophr Bull. 1982;8:470–484
  11. Erlenmeyer-Kimling L, Rock D, Roberts SA, et al. Attention, memory, and motor skills as childhood predictors of schizophrenia-related psychoses: the New York High-Risk Project. Am J Psychiatry. 2000;157:1416–1422
  12. Gochman PA, Greenstein D, Sporn A, et al. IQ stabilization in childhood-onset schizophrenia. Schizophr Res. 2005;77:271–277
  13. Gold JM. Cognitive deficits as treatment targets in schizophrenia. Schizophr Res. 2004;72:21–28
  14. Green MF, Kern RS, Heaton RK. Longitudinal studies of cognition and functional outcome in schizophrenia: implications for MATRICS. Schizophr Res. 2004;72:41–51
  15. Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr Bull. 2000;26:119–136
  16. Hales RE, Yudofsky SC. Textbook of Clinical Psychiatry. 4th ed.. Arlington, VA: American Psychiatric Publishing; 2003;
  17. Harvey PD, Meltzer H, Simpson GM, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101–113
  18. Heaton RK, Gladsjo JA, Palmer BW, Kuck J, Marcotte TD, Jeste DV. Stability and course of neuropsychological deficits in schizophrenia. Arch Gen Psychiatry. 2001;58:24–32
  19. Heinrichs RW, Zakzanis KK. Neurocognitive deficit in schizophrenia: a quantitative review of the evidence. Neuropsychology. 1998;12:426–445
  20. Hoff AL, Sakuma M, Wieneke M, Horon R, Kushner M, DeLisi LE. Longitudinal neuropsychological follow-up study of patients with first-episode schizophrenia. Am J Psychiatry. 1999;156:1336–1341
  21. Hollingshead A, Redlich F. Social Class and Mental Illness. New York: Wiley; 1958;
  22. Hollis C. Adult outcomes of child-and adolescent-onset schizophrenia: diagnostic stability and predictive validity. Am J Psychiatry. 2000;157:1652–1659
  23. Jaeger J, Tatsuoka C, Berns S, Varadi F, Czobor P, Uzelac S. Associating functional recovery with neurocognitive profiles identified using partially ordered classification models. Schizophr Res. 2006;85:40–48
  24. Kaufman J, Birmaher B, Brent D, et al. Schedule for Affective Disorders and schizophrenia for School-age Children-Present and Lifetime version: initial reliability and validity data. J Am Acad Child Adolesc Psychiatry. 1997;36:980–988
  25. Kern RS, Green MF, Cornblatt BA, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology. 2006;187:312–320
  26. Klingberg T, Fernell E, Olesen PJ, et al. Computerized training of working memory in children with ADHD-a randomized, controlled trial. J Am Acad Child Adolesc Psychiatry. 2005;44:177–186
  27. Kravariti E, Morris RG, Rabe-Hesketh S, Murray RM, Frangou S. The Maudsley early onset schizophrenia study: cognitive function in adolescents with recent onset schizophrenia. Schizophr Res. 2003;61:137–148
  28. Kumra S, Ashtari M, Cervellione KL, et al. White matter abnormalities in early-onset schizophrenia: a voxel-based diffusion tensor imaging study. J Am Acad Child Adolesc Psychiatry. 2005;44:934–941
  29. Kurtz MM. Neurocognitive rehabilitation for schizophrenia. Curr Psychiatry Rep. 2003;5:303–310
  30. Malhotra AK, Burdick KE, Razi K, Bates JA, Sanders M, Kane JM. Ziprasidone-induced cognitive enhancement in schizophrenia: specificity or pseudospecificity?. Schizophr Res. 2006;87:181–184
  31. Matza LS, Buchanan R, Purdon S, Brewster-Jordan J, Zhao Y, Revicki DA. Measuring changes in functional status among patients with schizophrenia: the link with cognitive impairment. Schizophr Bull. 2006;32:666–678
  32. McClellan J, McCurry C, Snell J, DuBose A. Early-onset psychotic disorders: course and outcome over a 2-year period. J Am Acad Child Adolesc Psychiatry. 1999;38:1380–1388
  33. McClellan J, Prezbindowski A, Breiger D, McCurry C. Neuropsychological functioning in early onset psychotic disorders. Schizophr Res. 2004;68:21–26
  34. Milev P, Ho BC, Arndt S, Andreasen NC. Predictive values of neurocognition and negative symptoms on functional outcome in schizophrenia: a longitudinal first-episode study with 7-year follow-up. Am J Psychiatry. 2005;162:495–506
  35. Nelson HE, O'Connell A. Dementia: the estimation of premorbid intelligence levels using the New Adult Reading Test. Cortex. 1978;14:234–244
  36. Overall J, Gorham D. The brief psychiatric rating scale. Psychiatry Res. 1962;10:799–812
  37. Penades R, Catalan R, Salamero M, et al. Cognitive remediation therapy for outpatients with chronic schizophrenia: a controlled and randomized study. Schizophr Res. 2006;87:323–331
  38. Rhinewine JP, Lencz T, Thaden EP, et al. Neurocognitive profile in adolescents with early-onset schizophrenia: clinical correlates. Biol Psychiatry. 2005;58:705–712
  39. Savla GN, Moore DJ, Roesch SC, Heaton RK, Jeste DV, Palmer BW. An evaluation of longitudinal performance among middle-aged and older schizophrenia patients: use of mixed-model analyses. Schizophr Res. 2006;83:215–223
  40. Schubert MH, Young KA, Hicks PB. Galantamine improves cognition in schizophrenia patients stabilized on risperidone. Biol Psychiatry. 2006;60:530–533
  41. Spreen O, Strauss E. A Compendium of Neuropsychological Tests. New York: Oxford University Press; 1998;
  42. Werry JS, McClellan JM. Predicting outcome in child and adolescent (early onset) schizophrenia and bipolar disorder. J Am Acad Child Adolesc Psychiatry. 1992;31:147–150
  43. Wilkinson GS. WRAT3: Wide Range Achievement Test Administration Manual. Wilmington, DE: Wide Range; 1993;
  44. Winters NC, Collett BR, Myers KM. Ten-year review of rating scales, VII: scales assessing functional impairment. J Am Acad Child Adolesc Psychiatry. 2005;44:309–342
  45. Woods SW. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry. 2003;64:663–667

 This work was supported in part by grants from NARSAD (S.K. as a Lieber Investigator), the National Institute of Mental Health to Dr. Kumra (MH 60229; MH 64556) and the General Clinical Research Center (RR 08535), an ACISR grant to Dr. Kane (MH 074543-01), and grants from the North Shore-Long Island Jewish Health System Research Institute.Article Plus (online only) material for this article appears on the Journal's Web site at www.jaacap.com.Disclosure: The authors have no financial relationships to disclose.

PII: S0890-8567(09)62175-4

doi: 10.1097/chi.0b013e318054678d

Journal of the American Academy of Child & Adolescent Psychiatry
Volume 46, Issue 7 , Pages 867-878 , July 2007

Article Tools

* Image Usage & Resolution